No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Quest Diagnostics Incorporated is a prominent provider of extensive diagnostic information services, operating throughout the United States and in international territories. The company specializes in developing and delivering a broad spectrum of diagnostic insights, including standard routine tests, highly specialized and advanced clinical analyses, anatomical pathology examinations, and other crucial diagnostic information services. These services are primarily offered under the flagship Quest Diagnostics brand, supplemented by specialized brands such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. The company caters to a diverse array of clients, including individual patients, medical professionals, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations. Service delivery is facilitated through a vast, integrated network comprising laboratories, dedicated patient service centers, on-site phlebotomists within physician offices, call centers for remote support, and mobile healthcare professionals like paramedics and nurses. Beyond its core diagnostic offerings, Quest Diagnostics also extends its expertise to provide risk assessment services tailored for the life insurance industry, and it equips healthcare organizations and clinicians with robust information technology solutions. Established in 1967, Quest Diagnostics Incorporated maintains its corporate headquarters in Secaucus, New Jersey.
www.questdiagnostics.comNo one on the platform currently holds 0KSX.L.
No tracked institution reports a position in 0KSX.L as of their last filing.
No one on the platform has traded 0KSX.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.9% | 11.4% | 11.3% | — | — | — |
| Rev. Growth % | 11.8% | 3.2% | ||||
| Profit Margin % | 9.0% | 11.0% | 11.0% | |||
| Free Cash Flow Margin % | 12.3% | 12.2% | 12.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $12.0B | +9.3% | $11.19 | $11.02–$11.38 | — | 1 |
| 2027 | $12.6B | +4.7% | $12.06 | $11.88–$12.26 | — | 1 |
| 2028 | $13.1B | +4.3% | $13.09 | $12.90–$13.32 | — | 1 |
| 2029 | $13.8B | +5.4% | $14.78 | $14.56–$15.03 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $2.82 | $3.12 | +10.6% |
| 2026-04-21 | $2.37 | $2.50 | +5.5% |
| 2026-02-10 | $2.36 | $2.42 | +2.5% |
| 2025-10-21 | $2.50 | $2.60 | +4.0% |
| 2025-07-22 | $2.57 | $2.62 | +1.9% |
| 2025-04-22 | $2.15 | $1.94 | -9.8% |
| 2025-01-30 | $2.19 | $2.23 | +1.8% |
| 2024-10-22 | $2.26 |
| $1.99 |
| -11.9% |
| +0.10% |
| $16.9B |
| — |
| 0J8Z.LIllumina, Inc. | $226.40 | +8.85% | $34.3B | — |
| 0J9P.LIncyte Corporation | $121.28 | -0.97% | $24.0B | — |
Source: Financial Modeling Prep · peers by sector/industry